Barclays’s BeOne Medicines Ltd ONC Stock Holding History

Barclays’s Portfolio ONC Stock Details ONC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.12M	Hold	10,500	–	–	﹤0.01%	2099
2025 Q4	$3.19M	Sell	10,500 -3,000	-22%	-$982K	﹤0.01%	2591
2025 Q3	$4.6M	Buy	+13,500	New	+$4.1M	﹤0.01%	2266
2024 Q4	–	Sell	-57,000	Closed	-$12.8M	–	5536
2024 Q3	$12.8M	Buy	57,000 +27,000	+90%	+$4.86M	﹤0.01%	1312
2024 Q2	$4.28M	Buy	+30,000	New	+$4.62M	﹤0.01%	1636
2024 Q1	–	Sell	-15,000	Closed	-$2.71M	–	5425
2023 Q4	$2.71M	Buy	+15,000	New	+$2.71M	﹤0.01%	2664
2018 Q4	–	Sell	-8,600	Closed	-$1.48M	–	7410
2018 Q3	$1.48M	Buy	+8,600	New	+$1.45M	﹤0.01%	3240

Other funds holding ONC

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Barclays's ONC Position: Q1 2026 in Review

Barclays increased its BeOne Medicines Ltd (ONC) stake by 1.7% in Q1 2026, buying an estimated $136K and bringing the position to 25,222 shares worth $7.49M. The position accounts for ﹤0.01% of the portfolio, ranked #1600.

Barclays first reported a position in ONC in Q4 2016 and has held it in 38 quarters since. The position peaked at $19.7M in Q4 2020. 281 funds tracked by Wall St. Rank hold ONC as of Q1 2026.

Barclays held 25,222 shares of BeOne Medicines Ltd worth $7.49M as of Q1 2026.
Barclays bought 421 BeOne Medicines Ltd shares in Q1 2026, an estimated $136K.
BeOne Medicines Ltd made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #1600 holding.
Barclays first reported a position in BeOne Medicines Ltd in Q4 2016 and has held it in 38 quarters since.
Barclays's BeOne Medicines Ltd position peaked at $19.7M in Q4 2020.
281 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.